Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Tirzepatide, a weight loss drug, shows promise in preventing diabetes by improving insulin sensitivity and aiding in weight ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by ...

Since June 1, Lilly has earned approval for brand-new medicines, including eczema treatment Ebglyss and a potential ...

The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...

Citi notes that the FDA said in a status report filed in a Texas court that it needs more time to determine if Eli Lilly’s (LLY) tirzepatide ...